Text Size

Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2007 by HaEmek Medical Center, Israel.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00491296
First received: June 19, 2007
Last updated: November 5, 2008
Last verified: June 2007
History of Changes
  Purpose

PURPOSE: We determined whether Synergo therapy- intravesical chemotherapy instillation combined with hyperthermia instillation is associated with elevated prostate specific antigen (PSA). MATERIALS AND METHODS: We will treat 25 consecutive patients with bladder cancer with a 6-week course of Synergo therapy, followed by cystoscopy at 6 weeks. Blood samples for PSA determination will obtain before each synergo therapy application and at cystoscopy with each patient also serving as a control.

Evaluating changes in PSA level in patients undergoing treatment with Synergo delivered local hyperthermia combined with intravesical instillation of Mitomycin C for adjuvant treatment or pt. with recurrent tu of bladder post TURT with BCGtreatment.


Condition Intervention
Bladder Cancer
 Device: SYNERGO
Device: SYNERGO-intravesical chemotherapy instillation combined with hyperthermia

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by HaEmek Medical Center, Israel:

Study Start Date: June 2007
Estimated Study Completion Date: June 2007
  Eligibility

Ages Eligible for Study:   30 Years to 90 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Recurrent transitional cell carcinoma of urinary bladder post endoscopic resection
  • PSA Prior synergo therapy application<10
  • Normal rectal examination
  • Patients willing to sign informed consent according

Exclusion Criteria:

  • History of prostate cancer
  • Previous history of TCC stage T2 or higher
  • Invasive tu of bladder
  • Prior pelvic radiotherapy or systemic chemotherapy
  • Active prostatitis
  • Active tuberculosis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00491296

Contacts
Contact: doron perez, M.D. +972-4-6495115 perez_do@clalit.org.il

Locations
Israel
Department of urology Not yet recruiting
Afula, Israel, 18101
Contact: doron perez, M.D.     +972-4-6495115     perez_do@clalit.org.il    
Haemek MC
Afula, Israel, 18100
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: PEREZ DORON, M.D. HAEMEK MEDICAL CENTER, UROLOGY DEPARTMENT
Principal Investigator: Perez Doron, M.D Haemek medical center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00491296     History of Changes
Other Study ID Numbers: 0034-07-EMC
Study First Received: June 19, 2007
Last Updated: November 5, 2008
Health Authority: Israel: Ethics Commission

Keywords provided by HaEmek Medical Center, Israel:
S/P Transuretral resection of bladder tumor
Recurrent tumor after BCG Treatment

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
 Neoplasms
Urinary Bladder Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on May 22, 2013